To the full analysis
Buyback calculator for 4D Molecular Therapeutics
4D Molecular Therapeutics stock: key metrics
FDMT4D Molecular Therapeutics had an operating margin of −187.2% and a return on invested capital (ROIC) of −23.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2017 | −134.4% | −194.7% | −193.8% |
| 2018 | −30.0% | −73.6% | −67.6% |
| 2019 | −454.2% | −726.7% | −705.8% |
| 2020 | −289.6% | −416.3% | −416.5% |
| 2021 | −240.2% | −395.5% | −395.4% |
| 2022 | −2,464.8% | −3,516.5% | −3,435.4% |
| 2023 | −368.5% | −544.6% | −486.6% |
| 2024 | −381,789.2% | −507,678.4% | −434,778.4% |
| 2025 | 91.1% | −187.2% | −164.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2017 | 57.3% | −41.6% | −41.1% |
| 2018 | 34.6% | −14.9% | −9.8% |
| 2019 | 67.6% | −59.8% | −84.7% |
| 2020 | −22.1% | −28.3% | −19.7% |
| 2021 | −22.3% | −18.5% | −20.2% |
| 2022 | −46.5% | −29.8% | −41.1% |
| 2023 | −32.8% | −31.4% | −29.7% |
| 2024 | −31.5% | −34.8% | −28.7% |
| 2025 | −27.7% | −23.9% | −24.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 11 Sep 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.